willow health glp 1 reviews GLP-1 Review 2026: Flat Pricing, Bumpy on Trust Willow Reviews | Read Customer

WARNING: Risk of Thyroid C-Cell Tumors In animal studies, GLP-1 receptor agonists have been associated with thyroid C-cell tumors, including medullary thyroid carcinoma (MTC)

As someone who has personally lost over 100 pounds and guided hundreds of women through this journey, I know how discouraging a weight loss plateau can feel

WeightWatchers' stock jumped 10% after the announcement

Trying to reuse the same single-use pen can similarly increase the risk of infection

TL;DR: The GLP-1 receptor agonist landscape in 2026 spans four distinct compounds: semaglutide (selective GLP-1 RA, MW 4113.58 Da, injectable and oral), tirzepatide (dual GLP-1/GIP agonist, MW 4813.45 Da), retatrutide (triple GLP-1/GIP/glucagon agonist, MW ~4500 Da, Phase 3), and orforglipron (non-peptide oral GLP-1 agonist, MW 541.65 Da, FDA-approved April 2026)